David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the 2018 Annual Meeting.
A perspective on the trade-offs between safety & efficacy in 1st line RCC
David I. Quinn, MD,the trade-offs between safety and efficacy in 1st line renal cell carcinoma (RCC) treatment options at the 2018 Annual Meeting.